


13. November 2026

Evidence to Push Forward on AMR: Is There an Optimal Form?

An International Workshop for Early-Career Researchers on Evidence, Methods and Policy for Antibiotic Innovation

Program



At a glance

A one-day international workshop for PhD students, postdoctoral researchers, early career researchers, and experts working on antibiotic innovation, antimicrobial resistance (AMR), health economics, and related policy questions. Its focus is not only on what the evidence on AMR says, but also on what form that evidence needs to take if it is to inform decisions, and in particular on what economic and social research contributes to prioritising action against AMR.

Why should you attend?

Antimicrobial resistance (AMR) is one of the greatest global health threats of our time, and addressing the market failure underlying antibiotic research and development (R&D) has become an increasing policy priority. Switzerland's revised Epidemics Act introduces a delinked subscription model to support antibiotic innovation, following pioneering initiatives in Sweden and the United Kingdom. As part of efforts to identify an appropriate model for Switzerland, we have been comparing alternative economic approaches to assessing the value of public investment in antibiotic innovation and quantifying its benefits for public health and society.

That work raised a broader question that extends well beyond the Swiss context: what form does evidence need to take to push forward action on AMR, and is there an optimal form? Economic analysis is central to this. It remains the principal means of comparing options and prioritising scarce resources across prevention, stewardship, diagnostics, surveillance, and innovation, but its outputs are only as useful as they are usable at the moment a decision is made. What alternative forms of evidence, including case studies, deliberative and qualitative work, scenario and narrative approaches, and One Health framings, exist for demonstrating the value of investing in tackling AMR, and how do they sit alongside economic evaluation rather than substitute for it? How can the evidence best support prioritisation, particularly in deciding where the next franc, pound, or euro should go in tackling AMR?

This workshop grew out of these questions. It aims to bring together early career researchers and leading experts to exchange ideas, compare methodological approaches, discuss emerging evidence, and identify priorities for future research on prioritising action on AMR. Above all, it asks participants to be explicit about the decisions their evidence is meant to inform, the audiences it must persuade, and what those audiences actually need in order to act.

Workshop Program

Bern, Switzerland, November 13, 2026

Session	Time	Topic
08:30 - 09:00 Coffee & Registration		
Opening Session	09:00 - 09:15	Welcome remarks by Jean Pierre Uwitonze
Keynote	09:15 - 09:45	<i>Framing the question</i> Chantal Morel
Presentation 1	9:45 - 10:10	<i>The Benefits of Prioritising a Good NAP: Estimating the Effect of AMR National Action Plans on Bacterial Resistance</i> Emily O'Neill
	10:10 - 10:25	Open Q&A
Presentation 2	10:25 - 10:50	<i>Towards a Social Cost of Antibiotic Resistance: Burden, Economic Evaluation and Optimal Prescribing</i> Giulio Cisco
	10:50 - 11:05	Open Q&A
11:05 - 11:20 Coffee break		
Presentation 3	11:20 - 11:45	<i>Financing the Antibiotic Pipeline: A Comparative Analysis of Three Economic Models</i> Jean Pierre Uwitonze
	11:45 - 12:00	Open Q&A
12:00 - 13:15 Lunch		
Presentation 4	13:15 - 13:40	<i>Science, Identities, and Polarization: A Policy Process Perspective on AMR Policymaking</i> Jule Ksinsik
	13:40 - 13:55	Open Q&A
Presentation 5	13:55 - 14:20	<i>When no one is in charge: antibiotic incentive reform and the Multiple Streams Framework in polycentric governance</i> Rudolf Blankart
	14:20 - 14:35	Open Q&A
Panel Discussion	14:35 - 15:10	Moderated by Chantal Morel
15:10 - 15:30 Coffee		
Outlook	15:30 - 15:35	<i>A word from Swiss RTA</i> Alicia Blair
Closing	15:35 - 15:50	Closing remarks by Jean Pierre Uwitonze

Last minute registration

[Evidence to Push Forward on AMR: Is There an Optimal Form? – Fill out form](#)